Articles by Emily Menendez
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
Sotorasib with panitumumab and FOLFIRI has shown promising long-term efficacy results in pretreated KRAS G12C–mutated ...
The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.
The guideline includes recommendations for the management of carcinoid syndrome and carcinoid heart disease.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
A multivariate analysis revealed HER2-targeted therapy to be an independent prognostic factor for OS.
Palliative EBRT can reduce physician-evaluated and patient-reported dysphagia symptoms in patients with incurable disease.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
CheckMate-8HW remains in progress to determine secondary end points such as overall survival.
Positive results from the phase 3 CABINET trial led to the treatment’s approval, which showed a median PFS of 13.8 months.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
Sassun-Mayo N/TNM staging demonstrated superior OS stratification compared with current AJCC staging.
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.